Kailera shares fall 10% on tolerability data for oral GLP-1 KAI-7535
HARBOR-1 in China showed 11.1% weight loss at 50 weeks, but nausea hit about 70% of treated patients versus 16.2% on placebo.
TR
By Tom Reyes · Markets Editor
Jul 8 03:00 ETSource: pharmaphorum.com
The wire
- 01KAI-7535 (HRS-7535), licensed from Hengrui, produced 11.1% weight loss at 50 weeks in the Chinese phase 3 HARBOR-1 trial; nausea was reported in about 70% and vomiting in more than 65% of patients.
- 02Efficacy sits near oral semaglutide and orforglipron, so GI tolerability becomes the differentiator for prescribers weighing oral obesity options.
- 03Kailera, which raised $625 million in its April Nasdaq IPO, says it is testing a lower starting dose and slower titration in an ex-China phase 2 trial reading out in 2027; no liver toxicity was seen.
From the source
Read at pharmaphorum.comKailera's big obesity reveal puts pressure on shares
Fresh from a record-breaking IPO, Kailera Therapeutics revealed keenly anticipated clinical trial results for its oral weight-loss drug, which prompted a 10% fall-off in its share price.